Acellular pertussis vaccine

Immunogenicity and safety of an acellular pertussis vs. a whole cell pertussis vaccine combined with diphtheria and tetanus toxoids as a booster in 18- to 24-month old children

Michael E. Pichichero, J. Thomas Badgett, George C. Rodgers, Samuel McLinn, Blanca Trevino-Scatterday, John D. Nelson

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

An acellular pertussis vaccine principally containing two purified pertussis antigens, filamentous hemagglutinin and lymphocytosis-promoting factor, combined with diphtheria and tetanus toxoids was compared to conventional diphtheria-tetanus toxoids-whole cell pertussis for adverse effects and serologic responses in a group of 120 children who were from 18 to 24 months of age. Three vaccinations at 2, 4 and 6 months of age with diphtheria-tetanus toxoids-whole cell pertussis had been administered previously. Adverse effects occurred more frequently with the diphtheria-tetanus toxoids-whole cell pertussis than with diphtheria-tetanus toxoids-acellular pertussis vaccine. Fever occurred significantly more often and to a higher degree in the whole cell pertussis vaccine recipients with a peak difference occurring 6 hours after immunization (P=0.00008). Local swelling, redness, warmth and tenderness at the injection site also occurred significantly more frequently following whole cell pertussis vaccination. No major sequelae were noted in either group. The antibody responses to lymphocytosis-promoting factor were similar for the two vaccines. The diphtheria-tetanus toxoids-acellular pertussis vaccine produced significantly lower pertussis agglutinin titers (P=0.00001). but significantly higher antibody to filamentous hemagglutinin (P= 0.05) and to diphtheria (P= 0.03). The protective role of antibody to pertussis agglutinins vs. filamentous hemagglutinin and lymphocytosis-promoting factor continues as a central issue in the quest for a new pertussis vaccine. A clinical efficacy trial is needed.

Original languageEnglish (US)
Pages (from-to)352-363
Number of pages12
JournalPediatric Infectious Disease Journal
Volume6
Issue number4
StatePublished - 1987

Fingerprint

Acellular Vaccines
Diphtheria Toxoid
Pertussis Vaccine
Tetanus Toxoid
Bordetella Virulence Factors
Whooping Cough
Safety
Diphtheria-Tetanus-acellular Pertussis Vaccines
Vaccination
Diphtheria
Antibodies
Pertussis Toxin
Hemagglutinins
Antibody Formation
Vaccine Immunogenicity
Immunization
Fever
Vaccines
Clinical Trials
Antigens

ASJC Scopus subject areas

  • Infectious Diseases
  • Microbiology (medical)
  • Pediatrics, Perinatology, and Child Health

Cite this

Acellular pertussis vaccine : Immunogenicity and safety of an acellular pertussis vs. a whole cell pertussis vaccine combined with diphtheria and tetanus toxoids as a booster in 18- to 24-month old children. / Pichichero, Michael E.; Badgett, J. Thomas; Rodgers, George C.; McLinn, Samuel; Trevino-Scatterday, Blanca; Nelson, John D.

In: Pediatric Infectious Disease Journal, Vol. 6, No. 4, 1987, p. 352-363.

Research output: Contribution to journalArticle

@article{153770a14c124ca682cc845d1a9c8c29,
title = "Acellular pertussis vaccine: Immunogenicity and safety of an acellular pertussis vs. a whole cell pertussis vaccine combined with diphtheria and tetanus toxoids as a booster in 18- to 24-month old children",
abstract = "An acellular pertussis vaccine principally containing two purified pertussis antigens, filamentous hemagglutinin and lymphocytosis-promoting factor, combined with diphtheria and tetanus toxoids was compared to conventional diphtheria-tetanus toxoids-whole cell pertussis for adverse effects and serologic responses in a group of 120 children who were from 18 to 24 months of age. Three vaccinations at 2, 4 and 6 months of age with diphtheria-tetanus toxoids-whole cell pertussis had been administered previously. Adverse effects occurred more frequently with the diphtheria-tetanus toxoids-whole cell pertussis than with diphtheria-tetanus toxoids-acellular pertussis vaccine. Fever occurred significantly more often and to a higher degree in the whole cell pertussis vaccine recipients with a peak difference occurring 6 hours after immunization (P=0.00008). Local swelling, redness, warmth and tenderness at the injection site also occurred significantly more frequently following whole cell pertussis vaccination. No major sequelae were noted in either group. The antibody responses to lymphocytosis-promoting factor were similar for the two vaccines. The diphtheria-tetanus toxoids-acellular pertussis vaccine produced significantly lower pertussis agglutinin titers (P=0.00001). but significantly higher antibody to filamentous hemagglutinin (P= 0.05) and to diphtheria (P= 0.03). The protective role of antibody to pertussis agglutinins vs. filamentous hemagglutinin and lymphocytosis-promoting factor continues as a central issue in the quest for a new pertussis vaccine. A clinical efficacy trial is needed.",
author = "Pichichero, {Michael E.} and Badgett, {J. Thomas} and Rodgers, {George C.} and Samuel McLinn and Blanca Trevino-Scatterday and Nelson, {John D.}",
year = "1987",
language = "English (US)",
volume = "6",
pages = "352--363",
journal = "Pediatric Infectious Disease Journal",
issn = "0891-3668",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Acellular pertussis vaccine

T2 - Immunogenicity and safety of an acellular pertussis vs. a whole cell pertussis vaccine combined with diphtheria and tetanus toxoids as a booster in 18- to 24-month old children

AU - Pichichero, Michael E.

AU - Badgett, J. Thomas

AU - Rodgers, George C.

AU - McLinn, Samuel

AU - Trevino-Scatterday, Blanca

AU - Nelson, John D.

PY - 1987

Y1 - 1987

N2 - An acellular pertussis vaccine principally containing two purified pertussis antigens, filamentous hemagglutinin and lymphocytosis-promoting factor, combined with diphtheria and tetanus toxoids was compared to conventional diphtheria-tetanus toxoids-whole cell pertussis for adverse effects and serologic responses in a group of 120 children who were from 18 to 24 months of age. Three vaccinations at 2, 4 and 6 months of age with diphtheria-tetanus toxoids-whole cell pertussis had been administered previously. Adverse effects occurred more frequently with the diphtheria-tetanus toxoids-whole cell pertussis than with diphtheria-tetanus toxoids-acellular pertussis vaccine. Fever occurred significantly more often and to a higher degree in the whole cell pertussis vaccine recipients with a peak difference occurring 6 hours after immunization (P=0.00008). Local swelling, redness, warmth and tenderness at the injection site also occurred significantly more frequently following whole cell pertussis vaccination. No major sequelae were noted in either group. The antibody responses to lymphocytosis-promoting factor were similar for the two vaccines. The diphtheria-tetanus toxoids-acellular pertussis vaccine produced significantly lower pertussis agglutinin titers (P=0.00001). but significantly higher antibody to filamentous hemagglutinin (P= 0.05) and to diphtheria (P= 0.03). The protective role of antibody to pertussis agglutinins vs. filamentous hemagglutinin and lymphocytosis-promoting factor continues as a central issue in the quest for a new pertussis vaccine. A clinical efficacy trial is needed.

AB - An acellular pertussis vaccine principally containing two purified pertussis antigens, filamentous hemagglutinin and lymphocytosis-promoting factor, combined with diphtheria and tetanus toxoids was compared to conventional diphtheria-tetanus toxoids-whole cell pertussis for adverse effects and serologic responses in a group of 120 children who were from 18 to 24 months of age. Three vaccinations at 2, 4 and 6 months of age with diphtheria-tetanus toxoids-whole cell pertussis had been administered previously. Adverse effects occurred more frequently with the diphtheria-tetanus toxoids-whole cell pertussis than with diphtheria-tetanus toxoids-acellular pertussis vaccine. Fever occurred significantly more often and to a higher degree in the whole cell pertussis vaccine recipients with a peak difference occurring 6 hours after immunization (P=0.00008). Local swelling, redness, warmth and tenderness at the injection site also occurred significantly more frequently following whole cell pertussis vaccination. No major sequelae were noted in either group. The antibody responses to lymphocytosis-promoting factor were similar for the two vaccines. The diphtheria-tetanus toxoids-acellular pertussis vaccine produced significantly lower pertussis agglutinin titers (P=0.00001). but significantly higher antibody to filamentous hemagglutinin (P= 0.05) and to diphtheria (P= 0.03). The protective role of antibody to pertussis agglutinins vs. filamentous hemagglutinin and lymphocytosis-promoting factor continues as a central issue in the quest for a new pertussis vaccine. A clinical efficacy trial is needed.

UR - http://www.scopus.com/inward/record.url?scp=0023179008&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023179008&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 352

EP - 363

JO - Pediatric Infectious Disease Journal

JF - Pediatric Infectious Disease Journal

SN - 0891-3668

IS - 4

ER -